Pfizer news from FierceBiotech
Founded: 1849
Based: New York
CEO: Jeffrey Kindler
2007 Revenue: $48.4 billion
Description: Pfizer is the world's largest research-based biomedical and pharmaceutical company. Corporate headquarters are located in New York, with major research and development locations in the United States and England. In 2006, Pfizer earned $48.4 billion in revenues and invested $7.6 billion in research and development.
NewsNicOx shares plunge on Pfizer trial failure
Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...
Esperion gets second shot as an independent drugmaker
After getting squashed in Pfizer's restructuring crunch, Esperion Therapeutics is reopening this week. The company, which specializes in cardiovascular and metabolic disease work, is hiring about 10 Read more...
Pfizer builds plant, creates jobs in Ireland
Pfizer has finally confirmed earlier reports about its plan to Read more...
Pfizer spins off Esperion as VCs ante up $22.75M
Pfizer has spun of Esperion Therapeutics into a new biotech company aiming to develop new therapies for cardiovascular and metabolic disease. A syndicate of investors funded the deal. Pfizer sold Read more...
ALSO NOTED: ISTA announces positive data; Proteolix launches Phase II trial; and much more...
> If anyone doubted Andrew Witty's professed faith in emerging markets, those doubts can be put to rest. The incoming GlaxoSmithKline CEO lured Eli Lilly's Abbas Hussein to spearhead a new unit Read more...
ALSO NOTED: Isotechnika reports psoriasis success; Romark enrolls hep C patients; and much more...
> Isotechnika's ISA247 has demonstrated significant efficacy against psoriasis. Report > Romark Laboratories Read more...
Pfizer, Avant ink $440M cancer vax deal
Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And Read more...
Codexis blueprints $100 million IPO
Codexis has decided to wade into frigid market waters with an IPO that may be used to raise upwards of $100 million. The company makes biocatalysts: enzymes or microbes that cause chemical Read more...
Inhaled insulin lung cancer warning riles investors
The inhaled insulin field got blitzed again today after Nektar Therapeutics and Pfizer reported an increased number of Read more...
Boehringer boasts of late-stage drug potential
A new self-assessment from Boehringer Ingelheim comes with some considerable boasting about the potential for new therapies and new indications now in its pipeline. Read more...
| Press ReleasesPfizerAnnounces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma Pfizer Inc. (PFE) Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma 4/2/2008 NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Read more... Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer SAN JOSE, Calif., Jan 07, 2008 -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, Read more... Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Read more... PRESS RELEASE: Pfizer to Acquire CovX to Extend Biotherapeutics Investment Pfizer to Acquire CovX to Extend Biotherapeutics Investment Acquisition Will Provide Innovative Biotherapeutics Technology Platform and Complementary Product Candidates in Oncology and Diabetes NEW Read more... PRESS RELEASE: Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds NEW YORK & EXTON, Pa. -- Dec 5, 2007 - Pfizer and Adolor Corporation announced Read more... |
Get more Pfizer coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight